These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7955820)

  • 1. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers.
    Lilleberg J; Antila S; Karlsson M; Nieminen MS; Pentkäinen PJ
    Clin Pharmacol Ther; 1994 Nov; 56(5):554-63. PubMed ID: 7955820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haemodynamic dose-efficacy of levosimendan in healthy volunteers.
    Lilleberg J; Sundberg S; Häyhä M; Akkila J; Nieminen MS
    Eur J Clin Pharmacol; 1994; 47(3):267-74. PubMed ID: 7867680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals.
    Sundberg S; Antila S; Scheinin H; Häyhä M; Virtanen M; Lehtonen L
    Int J Clin Pharmacol Ther; 1998 Dec; 36(12):629-35. PubMed ID: 9876999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan.
    Antila S; Honkanen T; Lehtonen L; Neuvonen PJ
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):446-9. PubMed ID: 9726699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic effects of the novel cardiotonic drug simendan: echocardiographic assessment in healthy volunteers.
    Lilleberg JM; Sundberg S; Leikola-Pelho T; Nieminen MS
    Cardiovasc Drugs Ther; 1994 Apr; 8(2):263-9. PubMed ID: 7918139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
    Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
    Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
    Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
    Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
    Harjola VP; Oikarinen L; Toivonen L; Jurkko R; Puttonen J; Sarapohja T; Sundberg S; Nieminen MS
    Int J Clin Pharmacol Ther; 2008 Aug; 46(8):389-99. PubMed ID: 18793580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery.
    Turanlahti M; Boldt T; Palkama T; Antila S; Lehtonen L; Pesonen E
    Pediatr Crit Care Med; 2004 Sep; 5(5):457-62. PubMed ID: 15329162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men.
    Sundberg S; Lilleberg J; Nieminen MS; Lehtonen L
    Am J Cardiol; 1995 May; 75(15):1061-6. PubMed ID: 7747690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin.
    Antila S; Jarvinen A; Honkanen T; Lehtonen L
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):705-10. PubMed ID: 11214780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system.
    Antoniades C; Antonopoulos AS; Tousoulis D; Bakogiannis C; Stefanadi E; Stefanadis C
    Curr Drug Metab; 2009 Feb; 10(2):95-103. PubMed ID: 19275545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of levosimendan in patients with congestive heart failure.
    Jonsson EN; Antila S; McFadyen L; Lehtonen L; Karlsson MO
    Br J Clin Pharmacol; 2003 Jun; 55(6):544-51. PubMed ID: 12814448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease.
    Põder P; Eha J; Antila S; Heinpalu M; Planken U; Loogna I; Mesikepp A; Akkila J; Lehtonen L
    Cardiovasc Drugs Ther; 2003; 17(5-6):451-8. PubMed ID: 15107600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site dependent bioavailability and metabolism of levosimendan in dogs.
    Antila S; Huuskonen H; Nevalainen T; Kanerva H; Vanninen P; Lehtonen L
    Eur J Pharm Sci; 1999 Oct; 9(1):85-91. PubMed ID: 10494001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of levosimendan on left ventricular function: correlation with plasma concentrations in conscious dogs.
    McGough MF; Pagel PS; Lowe D; Hettrick DA; Kersten JR; Warltier DC
    J Cardiothorac Vasc Anesth; 1997 Feb; 11(1):49-53. PubMed ID: 9058220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects.
    Sundberg S; Lehtonen L
    Eur J Clin Pharmacol; 2000; 55(11-12):793-9. PubMed ID: 10805056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.